Show simple item record

Authordc.contributor.authorMena, Natalia P. 
Authordc.contributor.authorGarcía Beltrán, Olimpo 
Authordc.contributor.authorLourido, Fernanda 
Authordc.contributor.authorUrrutia, Pamela J. 
Authordc.contributor.authorMena, Raúl 
Authordc.contributor.authorCastro Castillo, Vicente 
Authordc.contributor.authorCassels Niven, Bruce
Authordc.contributor.authorNúñez González, Marco 
Admission datedc.date.accessioned2015-11-03T20:24:37Z
Available datedc.date.available2015-11-03T20:24:37Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationBiochemical and Biophysical Research Communications 463 (2015) 787-792en_US
Identifierdc.identifier.otherDOI: 10.1016/j.bbrc.2015.06.014
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/134821
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractAbundant evidence indicates that iron accumulation, oxidative damage and mitochondrial dysfunction are common features of Huntington's disease, Parkinson's disease, Friedreich's ataxia and a group of disorders known as Neurodegeneration with Brain Iron Accumulation. In this study, we evaluated the effectiveness of two novel 8-OH-quinoline-based iron chelators, Q1 and Q4, to decrease mitochondrial iron accumulation and oxidative damage in cellular and animal models of PD. We found that at sub-micromolar concentrations, Q1 selectively decreased the mitochondrial iron pool and was extremely effective in protecting against rotenone-induced oxidative damage and death. Q4, in turn, preferentially chelated the cytoplasmic iron pool and presented a decreased capacity to protect against rotenone-induced oxidative damage and death. Oral administration of Q1 to mice protected substantia nigra pars compacta neurons against oxidative damage and MPTP-induced death. Taken together, our results support the concept that oral administration of Q1 is a promising therapeutic strategy for the treatment of NBIA.en_US
Patrocinadordc.description.sponsorshipCONICYT, Chile 3654593 FONDECYT 1130068 Program of Associative Research ACT1114en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherElsevieren_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectHydroxyquinolinesen_US
Keywordsdc.subjectIron chelationen_US
Keywordsdc.subjectMitochondriaen_US
Keywordsdc.subjectParkinson's diseaseen_US
Títulodc.titleThe novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal deathen_US
Document typedc.typeArtículo de revistaen_US


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile